NeuroMetrix Completes 510(k) Clearance Process for SENSUS™ Pain Management System WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 29, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes,

NeuroMetrix to Present at Canaccord Genuity Medical Technology & Diagnostics Forum WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 27, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes,

NeuroMetrix Announces Distribution Agreement with OneSource Medical Group for SENSUS Pain Management Device WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of

Commercial and Regulatory Progress in Diabetes Portfolio

NeuroMetrix, Inc. Announces Date for 2012 Third Quarter Financial Results Conference Call WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 15, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 third quarter financial results before the opening of the market on October 25, 2012 .

NeuroMetrix Receives Six Month Extension of Grace Period to Regain Compliance With NASDAQ Listing Requirements WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 20, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) stating that it

NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 5, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes,

NeuroMetrix Receives 510(k) Clearance for SENSUS™ Pain Management Device WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 6, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com , a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced

Commercial Progress in Diabetes Market

Comments on Early Detection of Diabetes-Related Nerve Disease